Protego Biopharma

Protego

This clinical-stage biotechnology company develops small molecule therapies that stabilise proteins to treat amyloidosis and other protein misfolding diseases for patients with organ damage.

Immutrin

This biotechnology company develops antibody therapies to remove amyloid deposits and treat cardiomyopathy for patients with amyloidosis.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

AMYL THERAPEUTICS

The company develops pan-amyloid immunotherapies to treat patients with neurodegenerative and rare diseases caused by toxic protein aggregates.

Trimtech Therapeutics

This biotechnology company develops small molecule drugs that target and degrade toxic protein aggregates to treat neurodegenerative and inflammatory diseases.

Eidos Therapeutics

This biopharmaceutical company develops acoramidis, a small molecule therapy designed to treat patients suffering from transthyretin amyloidosis by stabilising the transthyretin protein.

Protuoso Biosciences

This company develops multifunctional recombinant fusion proteins for pharmaceutical researchers and clinicians treating cardiometabolic, oncological and autoimmune diseases.

Origo Biopharma

This clinical-stage biotechnology company develops small molecule therapies targeting the transforming growth factor beta pathway to treat fibrosis and cancer in healthcare patients.